Roswell Park Comprehensive Cancer Center | Strategic Alliance Partners

Latest from Roswell Park Comprehensive Cancer Center


Roswell Park Researchers Propose 2 New Strategies for Treating Pancreatic Cancer

February 01, 2019

In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.

Roswell Park Transplant Specialists Explore New Strategies for Tackling GVHD

November 24, 2018

Investigators at Roswell Park Comprehensive Cancer Center in Buffalo, New York, are working on a variety of novel approaches, including developing prophylactic drug regimens, studying methods of rejuvenating the recipient’s immune system, and analyzing genetic characteristics to improve donor selection.

Dr. Wang on Results With Crenolanib Plus Chemotherapy in AML

February 20, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the results of the combination of crenolanib plus chemotherapy in a study of patients with acute myeloid leukemia.

Dr. Wang Discusses Treatment Options for FLT3-Mutated AML

February 09, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30, 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Photodynamic Therapy: Looking at Treatment of Early-Stage Oral Cancer in a New Light

October 24, 2017

Although surgery and radiotherapy are standard treatment modalities for grade T1/T2 oral cavity cancer, both approaches have well-documented limitations, including their association with adverse effects that lower quality of life for patients.

Epigenetic Studies May Unlock Clues to Gene Mutations

April 07, 2017

Researchers at Roswell Park Cancer Institute are formalizing their epigenetics program across dozens of disease research groups, with the goal of understanding what changes in the epigenome lead to cancer and identifying targeted, personalized ways to address these changes.

Dr. Puzanov on Management of Adverse Events in Melanoma

December 30, 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses ways to manage patients with melanoma who may experience adverse events in response to treatment with immunotherapy.

Dr. Puzanov on Sequencing Targeted Therapy and Immunotherapy in Melanoma

December 27, 2016

Igor Puzanov, MD, director, Early Phase Clinical Trials Program, chief of Melanoma, coleader, CCSG Experimental Therapeutics Program, professor of Oncology, Department of Medicine, Roswell Park Cancer Institute, discusses an ongoing study exploring the optimal sequence of immunotherapy agents and targeted therapies for patients with melanoma.

Taking Steps to Manage Adverse Events Associated with Checkpoint Inhibitors

November 29, 2016

The observed adverse events that have been associated with immunotherapy, especially immunotherapy combinations, have to be properly assessed against their clearly improved efficacy in patients with otherwise dismal prognosis from stage IV cancers.

Discussing Palliative Care Plans Earlier Improves Quality of Life

July 21, 2016

A team of researchers take a retrospective look at the patterns of how, when, and to whom palliative options are presented to patients with metastatic breast cancer, as an approach for gaining insight on how to improve care for patients with late-stage, terminal cancers.

Dr. Iyer on Treatment of Patients With Lung NETs

December 15, 2015

Renuka Iyer, MD, associate professor of Oncology, co-director, Liver and Pancreas Tumor Center, section chief for Gastrointestinal Oncology, Roswell Park Cancer Institute, assistant professor of Medicine, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, discusses treatment of patients with lung neuroendocrine tumors.